TITLE

Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress

AUTHOR(S)
Balkan, J.; Dogru-Abbasoglu, S.; Kanbagli �.; �evikbas, U.; Ayka�-Toker, G.; Uysal, M.
PUB. DATE
May 2001
SOURCE
Human & Experimental Toxicology;May2001, Vol. 20 Issue 5, p251
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Thioacetamide (TAA) administration (0.3 g/l of tap water for a period of 3 months) to rats resulted in hepatic cirrhosis as assessed by biochemical and histopathological findings. This treatment caused an increase in the levels of malondialdehyde (MDA) and diene conjugates (DCs) and a decrease in the levels of glutathione (GSH), vitamin E, vitamin C and the activities of glutathione peroxidase (GSH-Px) in the liver of rats. Superoxide dismutase (SOD) activities were unchanged. Taurine (2% w/w, added to the chow diet) was administered together with TAA (0.3 g/l of drinking water) for 3 months. Taurine was found to decrease TAA-induced hepatic lipid peroxidation and to increase TAA-depleted vitamin E levels and GSH-Px activities. Histopathological findings also suggested that taurine has an inhibitive effect on TAA-induced hepatic cirrhosis. These results indicate that taurine treatment has a protective effect against TAA-induced liver cirrhosis by decreasing oxidative stress. Human & Experimental Toxicology (2001) 20, 251�254.
ACCESSION #
4886214

Tags: TAURINE;  LIVER -- Cirrhosis -- Treatment;  ANTIOXIDANTS;  PHYSIOLOGY

 

Related Articles

  • Protective effect of aqueous extract of Leonotis nepaetifolia (L.)R.Br.on CCL4 induced hepatic damage. Radhika, J.; Pradeep, V.; Brindha, P. // Journal of Pharmacy Research;Mar2011, Vol. 4 Issue 3, p630 

    Liver is one of the most important organs in the biotransformation of food, drugs, and endogenous and exogenous substances. Herbal plants have been recently popularized in modern medicine, since many therapeutically important compounds are derived from them. From the literature review it is...

  • Prescribing Medications in Patients with Decompensated Liver Cirrhosis. Amarapurkar, Deepak N. // International Journal of Hepatology;2011, p1 

    Patients with decompensated liver cirrhosis have various serious complications which require multiple drugs for therapeutic or prophylactic use. Majority of the drugs are primarily metabolized and excreted by hepatobiliary system; hence, liver cell necrosis contributes to impaired drug handling...

  • Participation of aquaporin-1 in vascular changes and remodeling in cirrhotic liver. Iguchi, Hiroyoshi; Oda, Masaya; Yamazaki, Hitoshi; Yokomori, Hiroaki // Medical Molecular Morphology; 

    The pathophysiology of arterial capillary proliferation accompanying fibrosis in human cirrhosis remains unclear. However, evidence regarding the molecules participating in the pathophysiological process has been accumulating. Water channel proteins known as aquaporins (AQP)s, notably AQP-1,...

  • The Potential Effect of Special Formulas on Cirrhotic Rats. Hassan, Enayat M.; El-Kherbawy, Ghada M.; Ali, Mona A. M.; Dewidar, Omaima M. // Food & Nutrition Sciences;May2013, Vol. 4 Issue 5, p594 

    Liver protective effect of special formulas (1 and 2) was assessed against carbon tetra chloride (CCl4) which induced liver damage in Wister albino rats. The two prepared formulas reduced the changes in body weight and liver weight caused by CCl4 in rats. The toxicity of CCl4 is related to loss...

  • Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. Franca, Alex Vianey Callado; Giordano, Helena maria; Sev �-Pereira, Tiago; Soares, Elza Cotrim // Journal of Gastroenterology;2002, Vol. 37 Issue 2, p119 

    Background. The aim of this study was to determine whether a short course of ceftriaxone was sufficient to cure spontaneous bacterial peritonitis (SBP) in cirrhotic patients. Methods. We studied 33 cirrhotic patients with SBP. All of them were treated with ceftriaxone, 1.0 g IV, every 12 h...

  • Treatment in primary biliary cirrhosis. Parkhouse, J. // British Medical Journal (Clinical Research Edition);10/10/1987, Vol. 295 Issue 6603, p867 

    Focuses on the treatment of primary biliary cirrhosis in Great Britain. Assessment of thyroid functions with fatigue; Benefits of cholestyramine treatment; Certainty on the efficacy of the treatment affecting important pathogenic factors.

  • Cirrhosis may be amenable to telomerase treatment. Berger, Abi // BMJ: British Medical Journal (International Edition);02/26/2000, Vol. 320 Issue 7234, p536 

    Provides information on a study in Boston, Massachusetts which suggested that liver disease culminating in cirrhosis may be amenable to telomerase treatment. Methods and subjects used in the study; Comments from Ron DePinho, research leader and professor of medicine and genetics at Harvard...

  • Terlipressin and arterial blood volume after paracentesis for tense ascites in cirrhosis. Ranger, G. Singh // Gut;Nov2002, Vol. 51 Issue 5, p755 

    Comments on a study published in a previous issue of the periodical 'Gut,' which described the use of terlipressin in ameliorating the reduction in effective arterial blood volume in patients with cirrhosis.

  • The End-Organ Impairment in Liver Cirrhosis: Appointments for Critical Care. Figueiredo, Antonio; Romero-Bermejo, Francisco; Perdigoto, Rui; Marcelino, Paulo // Critical Care Research & Practice;2012, p1 

    Liver cirrhosis (LC) can lead to a clinical state of liver failure, which can exacerbate through the course of the disease. New therapies aimed to control the diverse etiologies are now more effective, although the disease may result in advanced stages of liver failure, where liver...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics